Do Black Men with Metastatic Castration-Resistant Prostate Cancer Have Worse Outcomes Than White Patients? A Nationwide VA Study
Abstract
Black men have a higher prostate cancer (PC) risk and mortality than white men. Whether these differences are due to lack of access to care or more aggressive biology is debated. However, a few small studies suggested black men may actually have better outcomes than white men when treated with metastatic castration-resistant PC (mCRPC) drugs. We hypothesize that black men with mCRPC will have similar responses to modern mCRPC therapies but worse compliance; after accounting for poorer compliance, black men will actually have better responses to these therapies than white men. Our objective is, to create a true nation-wide cohort from the Veterans Affairs (VA) Health System. Our preliminary analyses identified 46,535 men treated with one of 6 drugs for mCRPC (Cabazitaxel, Docetaxel, Abiraterone, Enzalutamide, Radium-223, and Sipuleucel-T). We will 1. Determine drug efficacy among black and white men with mCRPC; 2. Determine drug compliance among black and white men with mCRPC; and 3. Determine drug efficacy among black and white men with mCRPC after accounting for compliance.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1192589
Entities
People
- Jun Gong
Organizations
- Cedars-Sinai Medical Center